Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$30.4B
413M shares
52-week range
$71.00 – $149.75
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
3.2
EV / FCF (TTM)
16.2
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
www.zoetis.comNo one on the platform currently holds ZTS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 252,000 | $29.8M |
| Bridgewater Associatesas of 2026-03-31 | 50,739 | $6.0M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-20 | $0.5300 | 2026-09-01 |
| 2026-04-20 | $0.5300 | 2026-06-02 |
| 2026-01-20 | $0.5300 | 2026-03-03 |
| 2025-10-31 | $0.5000 | 2025-12-02 |
| 2025-07-18 | $0.5000 | 2025-09-03 |
| 2025-04-21 | $0.5000 | 2025-06-03 |
| 2025-01-21 | $0.5000 | 2025-03-04 |
| 2024-10-31 | $0.4320 | 2024-12-03 |
| 2024-07-18 | $0.4320 | 2024-09-04 |
| 2024-04-18 | $0.4320 | 2024-06-04 |
No one on the platform has traded ZTS yet.
| 2024-01-18 | $0.4320 | 2024-03-01 |
| 2023-10-31 | $0.3750 | 2023-12-01 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 27.2% | 27.2% | 24.3% | — | — | — |
| Rev. Growth % | 2.3% | 7.2% | ||||
| Profit Margin % | 28.2% | 27.0% | 24.1% | |||
| Free Cash Flow Margin % | 24.1% | 21.3% | 20.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.2% on the P/E track.
At today's price, your expected annual return is +9.7% on the P/E track.
At today's price, your expected annual return is +15.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.3B | -1.6% | $6.25 | $6.23–$6.30 | 11.7× | 10 |
| 2027 | $9.4B | +1.5% | $6.46 | $6.10–$6.89 | 11.4× | 11 |
| 2028 | $9.8B | +4.2% | $7.01 | $5.88–$8.18 | 10.5× | 6 |
| 2029 | $10.3B | +4.6% | $8.11 | $7.61–$8.75 | 9.0× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $1.85 | $1.87 | +1.1% |
| 2026-05-07 | $1.60 | $1.53 | -4.4% |
| 2026-02-12 | $1.40 | $1.48 | +5.7% |
| 2025-11-04 | $1.62 | $1.70 | +4.9% |
| 2025-08-05 | $1.62 | $1.76 | +8.6% |
| 2025-05-06 | $1.41 | $1.48 | +5.0% |
| 2025-02-13 | $1.37 | $1.40 | +2.2% |
| 2024-11-04 | $1.46 |
| $1.58 |
| +8.2% |
| $62.9B |
| — |
| ELANElanco Animal Health Incorporated | $23.00 | -0.63% | $11.5B | — |
| ELVElevance Health Inc. | $417.90 | -1.49% | $90.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ZTS The east west pipeline will be repaired in a couple of days. Buy more shares now.
View on StockTwits ↗
$ZTS Bouncing off support 👀 Price retested the 0.786 fib and bounced well and is just below the 50DMA. Reclaiming this level is an easy buy. A breakout will follow.
View on StockTwits ↗$ZTS bullish, adding. Even if demand dips profitability has been on an uptrend
View on StockTwits ↗
$ZTS looks like we're going to bounce off the trend line again, but I'm interested to see if it'll react to the 50-day moving average. Volume has been below average and we haven't had an above average volume day since the 17th of August. Just a very flat and trading sideways stock, I think we're just waiting for the next catalyst. Long-term, I see this going up 100% over the next 2-3 years.
View on StockTwits ↗
$QQQ Big pivot to beaten down value names ahead. Quality compounders trading at deep discounts like $ISRG $ZTS $NFLX $ROL and the like.
View on StockTwits ↗$ZTS Big rotation into beaten down value names ahead. The likes of this and $ISRG $NFLX $ROL
View on StockTwits ↗
$ZTS Burry increased his zts holdings calling the stock very cheap. Just buy and set a gtc sell order at $120 and you will be rewarded.
View on StockTwits ↗
Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS $FLUT $LULU $ZTS https://stocktwits.com/news/equity/markets/michael-burry-sells-flutter-to-pile-into-lulu-under-100-plus-a-new-bet-on-zts/cZtXHCxRBbi
View on StockTwits ↗
$ZTS i want to buy.in at this level but oil, bonds and rate hikes got me scared for next week. Fall and spring are peak screw worm times fyi.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.